Investigating pyruvate kinase as a treatment target for T-cell acute lymphoblastic leukemia.
Official title: The role of pyruvate kinase as a therapeutic target in T-ALL
Funded at Rutgers Biomedical and Health Sciences · NIH-11010354 · Data updated 2026-11-12
This study is looking at a type of blood cancer called T-cell acute lymphoblastic leukemia (T-ALL) to see if a special enzyme can be used to make current treatments work better, especially for kids and adults facing this tough illness.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | January 11, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $323,224 |
| NIH project number | 5R01CA285513-02 |
| Project ID | NIH-11010354 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children and adults diagnosed with T-cell acute lymphoblastic leukemia who have not responded well to current treatments.
✕Less likely to help
Patients with other types of leukemia or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research focuses on T-cell acute lymphoblastic leukemia (T-ALL), a serious blood cancer that primarily affects children but can also occur in adults. The study aims to explore the role of the enzyme pyruvate kinase as a potential therapeutic target, especially in combination with existing treatments like NOTCH1 signaling inhibitors. By understanding how pyruvate kinase contributes to the disease, researchers hope to develop more effective treatment strategies that could improve patient outcomes. The approach includes both laboratory experiments and potential clinical applications to enhance the effectiveness of current therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with T-ALL, potentially reducing resistance and relapse rates.
How similar studies have gone: Previous research has shown promise in targeting metabolic pathways in leukemia, suggesting that this approach could yield significant advancements in treatment.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Herranz, Daniel — Rutgers Biomedical and Health Sciences
- Study coordinator: Herranz, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.